#NeuroSense

Thiard News@F4F

@newsen.bsky.social

6 days ago

NeuroSense to Reveal Influential Long-Term Survival Data on PrimeC at Notable ALS Conference NeuroSense Therapeutics Ltd. will present significant long-term survival data from its Phase 2b trial for PrimeC at a prominent ALS conference on March 9, 2026.

NeuroSense to Reveal Influential Long-Term Survival Data on PrimeC at Notable ALS Conference #United_States #Cambridge #ALS_Study #NeuroSense #PrimeC

Thiard News@F4F

@newsen.bsky.social

3 weeks ago

NeuroSense's PrimeC Shows Significant Survival Benefits in ALS Patients, Reducing Death Risk by 65% NeuroSense Therapeutics reports considerable survival improvement in ALS patients treated with PrimeC, showcasing a 65% decline in mortality risk and notable longevity benefits.

NeuroSense's PrimeC Shows Significant Survival Benefits in ALS Patients, Reducing Death Risk by 65% #United_States #Cambridge #ALS #NeuroSense #PrimeC

Thiard News@F4F

@newsen.bsky.social

1 month ago

NeuroSense Strengthens Global Patent Strategy with New Australian Patent for PrimeC Treatments NeuroSense Therapeutics has received a new Australian patent for its treatment PrimeC, aiming to enhance global IP protection strategies. This supports ALS and Alzheimer's development.

NeuroSense Strengthens Global Patent Strategy with New Australian Patent for PrimeC Treatments #Cambridge #Australia #ALS #NeuroSense #PrimeC

Thiard News@F4F

@newsen.bsky.social

1 month ago

NeuroSense Secures U.S. Patent for Innovative Alzheimer's Treatment with PrimeC NeuroSense Therapeutics has been granted a crucial U.S. patent for PrimeC, a promising treatment for Alzheimer's disease, paving the way for innovative therapies.

NeuroSense Secures U.S. Patent for Innovative Alzheimer's Treatment with PrimeC #United_States #Cambridge #Alzheimer's #NeuroSense #PrimeC

Thiard News@F4F

@newsen.bsky.social

2 months ago

NeuroSense Therapeutics Welcomes Alzheimer's Expert Prof. Steven Arnold to its Scientific Advisory Board NeuroSense Therapeutics announces the addition of Prof. Steven E. Arnold to its Scientific Advisory Board, enhancing its focus on Alzheimer's disease research and treatment.

NeuroSense Therapeutics Welcomes Alzheimer's Expert Prof. Steven Arnold to its Scientific Advisory Board #USA #Cambridge #NeuroSense #Alzheimer’s_Disease #Steven_Arnold

Thiard News@F4F

@newsen.bsky.social

2 months ago

NeuroSense Highlights Positive Safety Profile for PrimeC in Alzheimer's Phase 2 Study Results NeuroSense Therapeutics has revealed the safety findings from their Phase 2 study on PrimeC in Alzheimer's, affirming its tolerability and paving the way for further analysis.

NeuroSense Highlights Positive Safety Profile for PrimeC in Alzheimer's Phase 2 Study Results #USA #Cambridge #Alzheimer's #NeuroSense #PrimeC

Thiard News@F4F

@newsen.bsky.social

3 months ago

NeuroSense Therapeutics Plans Pre-NDS Meeting with Health Canada for ALS Treatment in 2026 NeuroSense Therapeutics is set to hold a crucial pre-NDS meeting with Health Canada in April 2026 as it advances its ALS treatment, PrimeC.

NeuroSense Therapeutics Plans Pre-NDS Meeting with Health Canada for ALS Treatment in 2026 #Canada #Cambridge #ALS #NeuroSense #PrimeC

Thiard News@F4F

@newsen.bsky.social

3 months ago

NeuroSense Obtains FDA Approval to Start Pivotal Phase 3 Trial for ALS Treatment Using PrimeC NeuroSense Therapeutics has secured FDA clearance to initiate a pivotal Phase 3 trial of PrimeC for ALS treatment, marking a significant step in neurodegenerative disease research.

NeuroSense Obtains FDA Approval to Start Pivotal Phase 3 Trial for ALS Treatment Using PrimeC #United_States #Cambridge #ALS #NeuroSense #PrimeC

Thiard News@F4F

@newsen.bsky.social

4 months ago

NeuroSense Therapeutics Plans Investor Webinar to Discuss Milestones on December 8, 2025 NeuroSense Therapeutics Ltd. is set to host an investor webinar on December 8, 2025, detailing significant updates on its clinical trials and business objectives.

NeuroSense Therapeutics Plans Investor Webinar to Discuss Milestones on December 8, 2025 #ALS #NeuroSense #Alzheimer

Thiard News@F4F

@newsen.bsky.social

5 months ago

NeuroSense's PrimeC Shows Promise in Reducing Alzheimer's Disease Biomarkers Significantly NeuroSense Therapeutics has announced significant findings from its Phase 2b study of PrimeC, showing promising results in reducing Alzheimer's disease biomarkers.

NeuroSense's PrimeC Shows Promise in Reducing Alzheimer's Disease Biomarkers Significantly #United_States #Cambridge #Alzheimer's_Disease #NeuroSense #PrimeC

Thiard News@F4F

@newsen.bsky.social

6 months ago

NeuroSense's Innovative Drug Candidate Shows Promise in Treating Alzheimer's Dementia NeuroSense's latest drug candidate shows early indications of effectiveness in Alzheimer's patient-derived neurons, suggesting significant potential in neuroprotective therapy.

NeuroSense's Innovative Drug Candidate Shows Promise in Treating Alzheimer's Dementia #USA #Cambridge #Alzheimer's #NeuroSense #PrimeC

Thiard News@F4F

@newsen.bsky.social

6 months ago

NeuroSense Therapeutics Secures $500,000 Private Placement to Enhance Growth Strategy NeuroSense Therapeutics has announced a $500,000 private placement at a premium, funding pivotal growth in treating neurodegenerative diseases.

NeuroSense Therapeutics Secures $500,000 Private Placement to Enhance Growth Strategy #USA #Cambridge #NeuroSense #Private_Placement #Neurodegenerative

Thiard News@F4F

@newsen.bsky.social

7 months ago

NeuroSense Reports Significant Progress in ALS Treatment Development for 2025 NeuroSense Therapeutics highlights crucial advancements in its ALS treatment candidate PrimeC, revealing pivotal trials and financial updates from H1 2025.

NeuroSense Reports Significant Progress in ALS Treatment Development for 2025 #United_States #Cambridge #ALS #NeuroSense #PrimeC

Thiard News@F4F

@newsen.bsky.social

7 months ago

Aaron Lazar and NeuroSense CEO Alon Ben-Noon Discuss ALS Science in Special Podcast Event Join Aaron Lazar and NeuroSense's CEO Alon Ben-Noon for an insightful discussion on ALS, new treatment strategies, and community engagement in a live podcast.

Aaron Lazar and NeuroSense CEO Alon Ben-Noon Discuss ALS Science in Special Podcast Event #USA #Cambridge #NeuroSense #Aaron_Lazar #ALS_Podcast

Thiard News@F4F

@newsen.bsky.social

10 months ago

NeuroSense Therapeutics Achieves Manufacturing Milestone for PrimeC as Canadian Launch Nears NeuroSense Therapeutics has successfully scaled up production of PrimeC, paving the way for a rapid Canadian market entry targeting ALS treatment. This milestone sets the stage for addressing significant medical needs.

NeuroSense Therapeutics Achieves Manufacturing Milestone for PrimeC as Canadian Launch Nears #Canada #Cambridge #ALS #NeuroSense #PrimeC

Thiard News@F4F

@newsen.bsky.social

10 months ago

NeuroSense Therapeutics Shares Positive Updates on Clinical Trials and Strategic Partnerships with Shareholders NeuroSense Therapeutics has issued a letter to shareholders detailing progress in clinical trials, regulatory strategies, and ongoing partnerships, reflecting optimism for developments in ALS treatments.

NeuroSense Therapeutics Shares Positive Updates on Clinical Trials and Strategic Partnerships with Shareholders #United_States #Cambridge #ALS #NeuroSense #PrimeC

Thiard News@F4F

@newsen.bsky.social

11 months ago

NeuroSense Therapeutics Unveils Groundbreaking ALS Treatment Data from Phase 2b Trial NeuroSense Therapeutics has revealed promising Phase 2b trial results highlighting PrimeC's potential for ALS treatment, illuminating new insights on microRNA.

NeuroSense Therapeutics Unveils Groundbreaking ALS Treatment Data from Phase 2b Trial #USA #Cambridge #ALS #NeuroSense #PrimeC

Thiard News@F4F

@newsen.bsky.social

11 months ago

NeuroSense Therapeutics Shares Promising Year-End Results and Future Plans for ALS Treatment NeuroSense Therapeutics has made significant strides in ALS treatment development, reporting year-end financials and outlining its plans for the Phase 3 study of PrimeC.

NeuroSense Therapeutics Shares Promising Year-End Results and Future Plans for ALS Treatment #United_States #Cambridge #ALS #NeuroSense #PrimeC

Thiard News@F4F

@newsen.bsky.social

11 months ago

NeuroSense Therapeutics Unveils Promising Phase 2b Trial Results for ALS at AAN Annual Meeting At the upcoming AAN meeting, NeuroSense will reveal significant findings from its Phase 2b trial of PrimeC, a promising ALS therapy.

NeuroSense Therapeutics Unveils Promising Phase 2b Trial Results for ALS at AAN Annual Meeting #United_States #San_Diego #ALS #NeuroSense #PrimeC

Thiard News@F4F

@newsen.bsky.social

1 year ago

NeuroSense Successfully Meets Nasdaq Compliance with Minimum Equity Standards NeuroSense Therapeutics has regained compliance with Nasdaq's minimum equity requirement, marking a significant milestone in their journey towards advancing ALS treatments.

NeuroSense Successfully Meets Nasdaq Compliance with Minimum Equity Standards #United_States #Cambridge #NeuroSense #PrimeC #Therapeutics

Thiard News@F4F

@newsen.bsky.social

1 year ago

NeuroSense Therapeutics Partners with Global Firm to Advance ALS Treatment PrimeC NeuroSense Therapeutics has entered a term sheet with a top global pharmaceutical partner to advance their ALS treatment PrimeC, ensuring crucial funding.

NeuroSense Therapeutics Partners with Global Firm to Advance ALS Treatment PrimeC #United_States #Cambridge #NeuroSense #PrimeC #ALS_Treatment

Thiard News@F4F

@newsen.bsky.social

1 year ago

NeuroSense Therapeutics Announces Positive Developments in ALS Treatment and Financial Growth for Q3 2024 NeuroSense Therapeutics shares significant business updates, including successful ALS study results and Q3 2024 financial performance amidst ambitious growth plans.

NeuroSense Therapeutics Announces Positive Developments in ALS Treatment and Financial Growth for Q3 2024 #United_States #Cambridge #NeuroSense #PrimeC #ALS_Treatment

KStrategy&

@kstrategyand.bsky.social

1 year ago

Weekly Roundup - PHARMA - 16 December 2024 🔊AstraZeneca's Imfinzi Wins FDA Approval for Limited-Stage Small Cell Lung Cancer AstraZeneca's Imfinzi offers a new post-chemotherapy immunotherapy. The ADRIATIC trial showed survival benefits, makin...

Weekly Roundup - PHARMA - 16 December 2024

www.linkedin.com/pulse/weekly...

kstrategyand.com/pharma-news

#AstraZeneca #Imfinzi #Govorestat #Ozempic #Delgocitinib #SaudiArabia #GenScript #Tobevibart #Elebsiran #NeuroSense #PrimeC #Humanteconomy #Humantec #KStrategyand

Thiard News@F4F

@newsen.bsky.social

1 year ago

NeuroSense's Phase 3 Study for ALS Treatment Receives Positive FDA Feedback NeuroSense Therapeutics recently gained favorable FDA feedback on its Phase 3 study design for PrimeC, aimed at addressing ALS. This marks a significant milestone for the company.

NeuroSense's Phase 3 Study for ALS Treatment Receives Positive FDA Feedback #USA #Cambridge #ALS #NeuroSense #PrimeC

Thiard News@F4F

@newsen.bsky.social

1 year ago

NeuroSense Reports Positive PARADIGM Study Results for PrimeC in ALS Treatment NeuroSense Therapeutics showcases significant findings from the PARADIGM study, revealing PrimeC's efficacy and survival advantages in ALS. These insights may redefine treatment standards.

NeuroSense Reports Positive PARADIGM Study Results for PrimeC in ALS Treatment #United_States #Cambridge #ALS #NeuroSense #PrimeC

Thiard News@F4F

@newsen.bsky.social

1 year ago

NeuroSense Therapeutics Secures $5 Million for Neurodegenerative Disease Treatments NeuroSense Therapeutics has finalized a $5 million private placement to advance treatments for severe neurodegenerative diseases, targeting ALS and more.

NeuroSense Therapeutics Secures $5 Million for Neurodegenerative Disease Treatments #United_States #biotechnology #ALS #NeuroSense #Cambridge,_Massachusetts